New cancer immunotherapy
Many scientists and drug researchers are developing new immunotherapies. But failure has not deterred innovation, and a new combination of immunotherapies has emerged.
The key to this treatment lies in a receptor molecule called NKG2A. It is highly expressed on the surface of T cells and NK cells, and the binding of NKG2A with ligands inhibits the functions of T cells and NK cells.
This is very similar to the immune cell "brake" we mentioned above. Similarly, if NKG2A binding to ligand can be inhibited, it is expected to release the activity of immune cells. Following this line of thought, the researchers first performed an in vitro experiment. They found that both NKG2A antibody and pd-l1 antibody alone increased the activity of immune cells. And both use together, can play a significantly better effect.
The researchers then tested it in mouse models. This time, the NKG2A antibody alone did not have any effect, and the survival rate of the mice was similar to that of the control group. Pd-l1 alone saved about 40 percent of the lives of mice.
Here's an interesting thing. When NKG2A antibody was combined with pd-l1 antibody, the number jumped from 40% to 75%, almost doubling. This result also indicates that NKG2A antibody is expected to synergize with classical tumor immunotherapy to produce the effect of 1+1 greater than 2.
The key to this treatment lies in a receptor molecule called NKG2A. It is highly expressed on the surface of T cells and NK cells, and the binding of NKG2A with ligands inhibits the functions of T cells and NK cells.
This is very similar to the immune cell "brake" we mentioned above. Similarly, if NKG2A binding to ligand can be inhibited, it is expected to release the activity of immune cells. Following this line of thought, the researchers first performed an in vitro experiment. They found that both NKG2A antibody and pd-l1 antibody alone increased the activity of immune cells. And both use together, can play a significantly better effect.
The researchers then tested it in mouse models. This time, the NKG2A antibody alone did not have any effect, and the survival rate of the mice was similar to that of the control group. Pd-l1 alone saved about 40 percent of the lives of mice.
Here's an interesting thing. When NKG2A antibody was combined with pd-l1 antibody, the number jumped from 40% to 75%, almost doubling. This result also indicates that NKG2A antibody is expected to synergize with classical tumor immunotherapy to produce the effect of 1+1 greater than 2.
